ZNF683 and neoplasm: Consistent with previous findings (Meng et al, 2023), we observed that Tcr-1-positive CD8+ subclone was identified as high expression of GNLY, ZNF683, CXCL13 (Fig. 2H, and Appendix Fig. S3G), and were furtherly proven of high avidity against SYT-SSX fusion-positive tumor cells (Appendix Fig. S3G).